ADAM17 and lung cancer: In this regard, ADAM17 is overactivated via p38 MAPK-mediated threonine phosphorylation, following which, activated ADAM17 drives the preferential processing of the sIL-6R, which induces lung cancer cell proliferation through ERK1/2 MAPK activation.